|Bid||264,000.00 x 0|
|Ask||264,500.00 x 0|
|Day's range||267,500.00 - 279,500.00|
|52-week range||249,500.00 - 538,000.00|
|Beta (5Y monthly)||0.95|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2021 - 05 Nov 2021|
|Forward dividend & yield||1,500.00 (0.47%)|
|Ex-dividend date||29 Dec 2020|
|1y target est||N/A|
YONGIN, South Korea, August 12, 2021--GC Pharma (006280.KS) today announced the approval of GreenGene F (Beroctocog alfa) [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with haemophilia A in China by the National Medical Products Administration (NMPA). GreenGene F was initially approved by the Korean health authority in 2010 for control and prevention of bleeding episodes in patients with haemophilia A.
YONGIN, South Korea, August 11, 2021--GC Pharma (006280.KS) today announced that Frontiers in Immunology has published the safety and final efficacy results from the pivotal Phase III clinical trial of GC5107, its 10% Immune Globulin product for intravenous administration.
YONGIN, South Korea, August 02, 2021--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2021.